Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 145 | 2023 | 5181 | 8.790 |
Why?
|
Dexamethasone | 47 | 2023 | 1951 | 3.020 |
Why?
|
Thalidomide | 33 | 2023 | 890 | 2.570 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 67 | 2023 | 11525 | 2.500 |
Why?
|
Boronic Acids | 23 | 2015 | 965 | 1.650 |
Why?
|
Antineoplastic Agents | 42 | 2022 | 13693 | 1.520 |
Why?
|
Pyrazines | 23 | 2015 | 1230 | 1.480 |
Why?
|
Histone Deacetylase Inhibitors | 9 | 2021 | 789 | 1.280 |
Why?
|
Immunologic Factors | 15 | 2022 | 1580 | 1.050 |
Why?
|
Boron Compounds | 9 | 2021 | 178 | 1.030 |
Why?
|
Antibodies, Monoclonal | 21 | 2022 | 9274 | 0.970 |
Why?
|
Stem Cell Transplantation | 11 | 2022 | 1620 | 0.970 |
Why?
|
Glycine | 9 | 2021 | 671 | 0.890 |
Why?
|
Salvage Therapy | 9 | 2021 | 1275 | 0.810 |
Why?
|
Hydroxamic Acids | 5 | 2017 | 494 | 0.780 |
Why?
|
Hematopoietic Stem Cell Transplantation | 15 | 2022 | 5445 | 0.680 |
Why?
|
Phosphoramide Mustards | 1 | 2018 | 16 | 0.670 |
Why?
|
Drug Resistance, Neoplasm | 22 | 2021 | 5172 | 0.640 |
Why?
|
Blood Viscosity | 1 | 2018 | 124 | 0.640 |
Why?
|
Nitroimidazoles | 1 | 2018 | 106 | 0.610 |
Why?
|
Transplantation, Autologous | 14 | 2022 | 2124 | 0.590 |
Why?
|
Indoles | 6 | 2017 | 1839 | 0.590 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2023 | 9240 | 0.550 |
Why?
|
Recurrence | 23 | 2020 | 8340 | 0.530 |
Why?
|
Maximum Tolerated Dose | 10 | 2021 | 892 | 0.460 |
Why?
|
Melphalan | 5 | 2022 | 431 | 0.430 |
Why?
|
Receptors, CXCR4 | 4 | 2021 | 727 | 0.410 |
Why?
|
Waldenstrom Macroglobulinemia | 4 | 2020 | 1052 | 0.410 |
Why?
|
Humans | 165 | 2023 | 744366 | 0.390 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 4 | 2019 | 177 | 0.390 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2011 | 190 | 0.370 |
Why?
|
Clinical Trials as Topic | 15 | 2018 | 7914 | 0.360 |
Why?
|
Antibodies | 1 | 2018 | 2460 | 0.350 |
Why?
|
Disease-Free Survival | 19 | 2022 | 6896 | 0.350 |
Why?
|
Bone Marrow | 8 | 2023 | 2948 | 0.340 |
Why?
|
Molecular Targeted Therapy | 3 | 2021 | 2725 | 0.340 |
Why?
|
Erythroid Precursor Cells | 1 | 2009 | 218 | 0.330 |
Why?
|
Oligopeptides | 1 | 2014 | 1189 | 0.330 |
Why?
|
Aged | 62 | 2022 | 163288 | 0.320 |
Why?
|
Polycythemia Vera | 1 | 2009 | 164 | 0.310 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 8642 | 0.300 |
Why?
|
Standard of Care | 1 | 2011 | 564 | 0.290 |
Why?
|
Treatment Outcome | 38 | 2022 | 63107 | 0.290 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2018 | 841 | 0.280 |
Why?
|
Thrombocytopenia | 5 | 2023 | 1178 | 0.260 |
Why?
|
Drug Administration Schedule | 7 | 2021 | 4933 | 0.260 |
Why?
|
Leukemia, Myeloid | 1 | 2008 | 707 | 0.260 |
Why?
|
Practice Guidelines as Topic | 5 | 2021 | 7282 | 0.250 |
Why?
|
Middle Aged | 59 | 2022 | 213390 | 0.250 |
Why?
|
Retreatment | 4 | 2018 | 610 | 0.240 |
Why?
|
Aged, 80 and over | 32 | 2021 | 57776 | 0.240 |
Why?
|
Dementia | 1 | 2018 | 2518 | 0.240 |
Why?
|
Heterocyclic Compounds | 2 | 2022 | 249 | 0.240 |
Why?
|
Male | 69 | 2023 | 350115 | 0.240 |
Why?
|
ras Proteins | 1 | 2009 | 1060 | 0.240 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2017 | 685 | 0.220 |
Why?
|
Disease Progression | 9 | 2022 | 13286 | 0.220 |
Why?
|
Hypercalcemia | 2 | 2018 | 409 | 0.210 |
Why?
|
Female | 67 | 2023 | 380193 | 0.210 |
Why?
|
Protease Inhibitors | 3 | 2019 | 791 | 0.210 |
Why?
|
Thiadiazines | 1 | 2021 | 10 | 0.200 |
Why?
|
Administration, Oral | 6 | 2020 | 3914 | 0.200 |
Why?
|
Antibodies, Bispecific | 1 | 2023 | 164 | 0.200 |
Why?
|
Renal Insufficiency | 3 | 2012 | 804 | 0.190 |
Why?
|
Proteasome Endopeptidase Complex | 3 | 2017 | 1335 | 0.190 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2022 | 629 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 7 | 2019 | 6539 | 0.180 |
Why?
|
Immunoglobulin kappa-Chains | 2 | 2017 | 173 | 0.180 |
Why?
|
Immunotherapy | 7 | 2022 | 4446 | 0.180 |
Why?
|
Adenine | 3 | 2020 | 936 | 0.180 |
Why?
|
Drug Design | 2 | 2017 | 1076 | 0.180 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2009 | 2938 | 0.180 |
Why?
|
Immunosuppressive Agents | 2 | 2009 | 4153 | 0.170 |
Why?
|
Amyloidosis | 2 | 2018 | 796 | 0.170 |
Why?
|
Pharmacy | 1 | 2021 | 91 | 0.170 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 290 | 0.170 |
Why?
|
Phenylalanine | 1 | 2020 | 365 | 0.170 |
Why?
|
Hypotension, Orthostatic | 1 | 2022 | 255 | 0.170 |
Why?
|
Venous Thromboembolism | 2 | 2022 | 1671 | 0.170 |
Why?
|
Survival Rate | 12 | 2020 | 12788 | 0.170 |
Why?
|
Receptors, Immunologic | 2 | 2015 | 1423 | 0.160 |
Why?
|
Survival Analysis | 9 | 2021 | 10252 | 0.160 |
Why?
|
Hematopoiesis | 2 | 2020 | 2073 | 0.160 |
Why?
|
Leukemia, Plasma Cell | 1 | 2018 | 48 | 0.160 |
Why?
|
Diphosphonates | 2 | 2014 | 623 | 0.160 |
Why?
|
Neoplasm Staging | 8 | 2021 | 11031 | 0.160 |
Why?
|
Plasmapheresis | 1 | 2018 | 211 | 0.150 |
Why?
|
Follow-Up Studies | 13 | 2021 | 39052 | 0.150 |
Why?
|
Immunoglobulin M | 3 | 2017 | 1537 | 0.150 |
Why?
|
Immunoglobulin A | 2 | 2018 | 995 | 0.150 |
Why?
|
Tumor Microenvironment | 5 | 2019 | 3590 | 0.150 |
Why?
|
Lactones | 2 | 2017 | 329 | 0.150 |
Why?
|
Remission Induction | 5 | 2015 | 2385 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2020 | 10943 | 0.140 |
Why?
|
Piperidines | 3 | 2020 | 1602 | 0.140 |
Why?
|
Cell Proliferation | 4 | 2015 | 10483 | 0.140 |
Why?
|
Pyrazoles | 3 | 2018 | 1972 | 0.140 |
Why?
|
Imidazoles | 2 | 2014 | 1206 | 0.140 |
Why?
|
Apoptosis | 4 | 2019 | 9724 | 0.140 |
Why?
|
Adult | 37 | 2022 | 214052 | 0.140 |
Why?
|
Hallucinations | 1 | 2018 | 360 | 0.140 |
Why?
|
Bone Density Conservation Agents | 2 | 2014 | 772 | 0.130 |
Why?
|
Drug Screening Assays, Antitumor | 4 | 2011 | 730 | 0.130 |
Why?
|
Scleromyxedema | 1 | 2014 | 8 | 0.130 |
Why?
|
Pyrimidines | 3 | 2018 | 2943 | 0.130 |
Why?
|
Amyloid Neuropathies, Familial | 1 | 2017 | 138 | 0.130 |
Why?
|
Heart Diseases | 2 | 2018 | 2789 | 0.130 |
Why?
|
Granuloma Annulare | 1 | 2014 | 28 | 0.120 |
Why?
|
Blood Grouping and Crossmatching | 1 | 2015 | 108 | 0.120 |
Why?
|
Cardiovascular Diseases | 2 | 2017 | 15160 | 0.120 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2018 | 627 | 0.120 |
Why?
|
Transplantation Conditioning | 2 | 2018 | 1599 | 0.120 |
Why?
|
Cardiomyopathy, Restrictive | 1 | 2014 | 60 | 0.120 |
Why?
|
Immunoglobulin D | 1 | 2013 | 56 | 0.120 |
Why?
|
Doxorubicin | 2 | 2011 | 2234 | 0.120 |
Why?
|
Drug Evaluation, Preclinical | 3 | 2015 | 1375 | 0.120 |
Why?
|
Benzoates | 1 | 2015 | 217 | 0.110 |
Why?
|
Hydrazines | 1 | 2015 | 226 | 0.110 |
Why?
|
Azepines | 1 | 2015 | 334 | 0.110 |
Why?
|
Hypersensitivity, Delayed | 1 | 2014 | 484 | 0.110 |
Why?
|
Pyrroles | 2 | 2017 | 1146 | 0.110 |
Why?
|
Cryoglobulins | 1 | 2012 | 59 | 0.110 |
Why?
|
Drugs, Investigational | 1 | 2015 | 214 | 0.110 |
Why?
|
Plant Growth Regulators | 1 | 2012 | 50 | 0.110 |
Why?
|
Oxylipins | 1 | 2012 | 49 | 0.110 |
Why?
|
Cyclopentanes | 1 | 2012 | 91 | 0.110 |
Why?
|
Osteonecrosis | 1 | 2014 | 227 | 0.110 |
Why?
|
Cryoglobulinemia | 1 | 2012 | 87 | 0.100 |
Why?
|
Clodronic Acid | 1 | 2011 | 60 | 0.100 |
Why?
|
Brain | 1 | 2018 | 26388 | 0.100 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2021 | 1862 | 0.100 |
Why?
|
Acetates | 1 | 2012 | 311 | 0.100 |
Why?
|
Megakaryocytes | 1 | 2015 | 545 | 0.100 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2011 | 434 | 0.090 |
Why?
|
Histone Deacetylases | 2 | 2013 | 728 | 0.090 |
Why?
|
Models, Psychological | 1 | 2015 | 811 | 0.090 |
Why?
|
Bone Remodeling | 1 | 2014 | 575 | 0.090 |
Why?
|
Benchmarking | 1 | 2017 | 1042 | 0.090 |
Why?
|
Asthenia | 1 | 2010 | 16 | 0.090 |
Why?
|
Adenosine A2 Receptor Agonists | 1 | 2010 | 27 | 0.090 |
Why?
|
Drug Therapy, Combination | 4 | 2014 | 6489 | 0.090 |
Why?
|
Prognosis | 11 | 2022 | 29060 | 0.090 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2021 | 2917 | 0.090 |
Why?
|
Neoplasm Proteins | 2 | 2019 | 3707 | 0.090 |
Why?
|
MAP Kinase Kinase Kinase 1 | 1 | 2009 | 58 | 0.090 |
Why?
|
Culture Media, Serum-Free | 1 | 2009 | 158 | 0.090 |
Why?
|
Osteolysis | 1 | 2011 | 270 | 0.090 |
Why?
|
Luminescent Measurements | 1 | 2012 | 405 | 0.090 |
Why?
|
Hospitals | 1 | 2023 | 3954 | 0.090 |
Why?
|
Desensitization, Immunologic | 1 | 2014 | 483 | 0.090 |
Why?
|
Time Factors | 5 | 2020 | 40075 | 0.080 |
Why?
|
Dyspnea | 1 | 2017 | 1303 | 0.080 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2009 | 197 | 0.080 |
Why?
|
Stem Cell Factor | 1 | 2009 | 219 | 0.080 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2010 | 215 | 0.080 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7721 | 0.080 |
Why?
|
Cell Line, Tumor | 8 | 2021 | 16690 | 0.080 |
Why?
|
High-Throughput Screening Assays | 2 | 2012 | 944 | 0.080 |
Why?
|
Drug Discovery | 1 | 2017 | 1058 | 0.080 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2012 | 624 | 0.080 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2716 | 0.080 |
Why?
|
Neoplastic Stem Cells | 2 | 2019 | 1376 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2018 | 9955 | 0.080 |
Why?
|
HIV Seronegativity | 1 | 2009 | 211 | 0.080 |
Why?
|
Myeloid Cells | 1 | 2013 | 810 | 0.080 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2009 | 134 | 0.080 |
Why?
|
Diagnosis, Differential | 3 | 2018 | 12961 | 0.080 |
Why?
|
Angiogenesis Inhibitors | 3 | 2019 | 2038 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3595 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 4 | 2021 | 5534 | 0.080 |
Why?
|
Bone and Bones | 2 | 2017 | 2576 | 0.080 |
Why?
|
Antigens, CD34 | 1 | 2009 | 659 | 0.080 |
Why?
|
Genomics | 2 | 2021 | 5717 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 1790 | 0.070 |
Why?
|
Sirolimus | 2 | 2014 | 1565 | 0.070 |
Why?
|
Vincristine | 1 | 2009 | 1039 | 0.070 |
Why?
|
Immunoglobulin E | 1 | 2013 | 1463 | 0.070 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2011 | 671 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1062 | 0.070 |
Why?
|
Kidney | 2 | 2014 | 7184 | 0.070 |
Why?
|
Bone Diseases | 1 | 2011 | 416 | 0.070 |
Why?
|
Delirium | 1 | 2018 | 1610 | 0.070 |
Why?
|
Authorship | 1 | 2010 | 271 | 0.070 |
Why?
|
Epigenesis, Genetic | 2 | 2017 | 3646 | 0.070 |
Why?
|
Flavonoids | 1 | 2009 | 443 | 0.070 |
Why?
|
Lymph Nodes | 2 | 2015 | 3476 | 0.070 |
Why?
|
Janus Kinase 2 | 1 | 2009 | 528 | 0.070 |
Why?
|
Immunoblotting | 1 | 2009 | 1683 | 0.070 |
Why?
|
Treatment Failure | 3 | 2022 | 2618 | 0.070 |
Why?
|
Fatigue | 3 | 2022 | 1531 | 0.070 |
Why?
|
Risk Factors | 8 | 2022 | 72296 | 0.070 |
Why?
|
Hematology | 1 | 2009 | 221 | 0.070 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2015 | 2455 | 0.070 |
Why?
|
Cancer Vaccines | 1 | 2013 | 1023 | 0.070 |
Why?
|
Retrospective Studies | 9 | 2023 | 77460 | 0.070 |
Why?
|
Animals | 12 | 2021 | 168768 | 0.070 |
Why?
|
Erythropoiesis | 1 | 2009 | 706 | 0.070 |
Why?
|
Erythrocytes | 1 | 2015 | 2455 | 0.070 |
Why?
|
Drug Hypersensitivity | 1 | 2014 | 884 | 0.070 |
Why?
|
Mutation | 4 | 2021 | 29786 | 0.060 |
Why?
|
Erythropoietin | 1 | 2009 | 726 | 0.060 |
Why?
|
Conflict of Interest | 1 | 2010 | 544 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2460 | 0.060 |
Why?
|
Adrenal Cortex Hormones | 1 | 2014 | 1856 | 0.060 |
Why?
|
Quality of Life | 6 | 2022 | 12802 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2009 | 2504 | 0.060 |
Why?
|
Disclosure | 1 | 2010 | 736 | 0.060 |
Why?
|
Research Personnel | 1 | 2009 | 573 | 0.060 |
Why?
|
B-Lymphocytes | 2 | 2014 | 4666 | 0.060 |
Why?
|
Drug Industry | 1 | 2010 | 746 | 0.060 |
Why?
|
Tumor Cells, Cultured | 3 | 2021 | 6313 | 0.060 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2010 | 1381 | 0.050 |
Why?
|
Melanoma | 1 | 2021 | 5511 | 0.050 |
Why?
|
Career Choice | 1 | 2009 | 744 | 0.050 |
Why?
|
Dendritic Cells | 1 | 2013 | 2725 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4751 | 0.050 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2022 | 227 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2013 | 4561 | 0.050 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2009 | 2016 | 0.050 |
Why?
|
Genes, Overlapping | 1 | 2021 | 36 | 0.050 |
Why?
|
Cell Survival | 4 | 2012 | 5882 | 0.050 |
Why?
|
Anemia | 1 | 2011 | 1503 | 0.050 |
Why?
|
Drug Administration Routes | 1 | 2021 | 153 | 0.050 |
Why?
|
Gene Expression | 2 | 2009 | 7798 | 0.050 |
Why?
|
Teaching | 1 | 2009 | 1174 | 0.050 |
Why?
|
Cyclin-Dependent Kinase 9 | 1 | 2021 | 66 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15535 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2018 | 6364 | 0.050 |
Why?
|
Acute Kidney Injury | 1 | 2013 | 1968 | 0.050 |
Why?
|
Exanthema | 2 | 2016 | 501 | 0.050 |
Why?
|
Phosphorylcholine | 2 | 2011 | 162 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2012 | 2962 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 648 | 0.040 |
Why?
|
Molecular Biology | 1 | 2023 | 596 | 0.040 |
Why?
|
T-Lymphocytes | 2 | 2013 | 10183 | 0.040 |
Why?
|
Propylene Glycol | 1 | 2018 | 32 | 0.040 |
Why?
|
Spain | 1 | 2020 | 465 | 0.040 |
Why?
|
Periodicals as Topic | 1 | 2010 | 1431 | 0.040 |
Why?
|
Benzylamines | 1 | 2019 | 223 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2020 | 667 | 0.040 |
Why?
|
Dioxygenases | 1 | 2020 | 316 | 0.040 |
Why?
|
Prednisone | 2 | 2014 | 1574 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 8432 | 0.040 |
Why?
|
Phosphorylation | 1 | 2009 | 8436 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 2010 | 1832 | 0.040 |
Why?
|
Crystallography, X-Ray | 2 | 2013 | 2012 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2009 | 3799 | 0.040 |
Why?
|
Coculture Techniques | 2 | 2013 | 1341 | 0.040 |
Why?
|
Rubella | 1 | 2018 | 48 | 0.040 |
Why?
|
Acute Disease | 1 | 2008 | 7147 | 0.040 |
Why?
|
Denmark | 1 | 2020 | 738 | 0.040 |
Why?
|
Myeloablative Agonists | 1 | 2018 | 218 | 0.040 |
Why?
|
Immunoelectrophoresis | 1 | 2017 | 110 | 0.040 |
Why?
|
Death Certificates | 1 | 2018 | 169 | 0.040 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 2017 | 87 | 0.040 |
Why?
|
Herpes Zoster Vaccine | 1 | 2018 | 47 | 0.040 |
Why?
|
Cells, Cultured | 2 | 2013 | 19233 | 0.040 |
Why?
|
Drug Compounding | 1 | 2018 | 242 | 0.040 |
Why?
|
Mumps | 1 | 2018 | 64 | 0.040 |
Why?
|
Proton Pump Inhibitors | 1 | 2022 | 526 | 0.040 |
Why?
|
Sweden | 1 | 2020 | 1341 | 0.040 |
Why?
|
Drug Synergism | 2 | 2012 | 1794 | 0.040 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 307 | 0.040 |
Why?
|
Medical Oncology | 1 | 2009 | 2267 | 0.040 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 693 | 0.040 |
Why?
|
Oncogene Proteins | 1 | 2021 | 749 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2012 | 4253 | 0.030 |
Why?
|
Prospective Studies | 5 | 2022 | 53290 | 0.030 |
Why?
|
Measles | 1 | 2018 | 168 | 0.030 |
Why?
|
Administration, Cutaneous | 1 | 2018 | 711 | 0.030 |
Why?
|
Lung | 1 | 2014 | 9857 | 0.030 |
Why?
|
Signal Transduction | 4 | 2015 | 23404 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2019 | 498 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11126 | 0.030 |
Why?
|
Netherlands | 1 | 2020 | 2170 | 0.030 |
Why?
|
Dithiothreitol | 1 | 2015 | 101 | 0.030 |
Why?
|
Stromal Cells | 2 | 2011 | 1355 | 0.030 |
Why?
|
Interleukin-3 | 1 | 1996 | 444 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 2 | 2012 | 1837 | 0.030 |
Why?
|
Biopsy | 2 | 2019 | 6755 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 25039 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2021 | 12025 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2065 | 0.030 |
Why?
|
Plasmacytoma | 1 | 2015 | 183 | 0.030 |
Why?
|
HL-60 Cells | 1 | 2015 | 365 | 0.030 |
Why?
|
Mice | 4 | 2021 | 81201 | 0.030 |
Why?
|
Biomedical Research | 1 | 2010 | 3309 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3338 | 0.030 |
Why?
|
Receptors, Thrombopoietin | 1 | 2015 | 157 | 0.030 |
Why?
|
Plasma Cells | 1 | 2017 | 591 | 0.030 |
Why?
|
Frail Elderly | 1 | 2018 | 693 | 0.030 |
Why?
|
Phase Transition | 1 | 2013 | 74 | 0.030 |
Why?
|
Cytokines | 3 | 2014 | 7323 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2018 | 973 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2015 | 5974 | 0.030 |
Why?
|
Heart Failure | 1 | 2017 | 10895 | 0.030 |
Why?
|
Cross Reactions | 1 | 2015 | 841 | 0.030 |
Why?
|
Serologic Tests | 1 | 2015 | 374 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2021 | 1707 | 0.030 |
Why?
|
Solutions | 1 | 2013 | 426 | 0.030 |
Why?
|
Buffers | 1 | 2012 | 147 | 0.030 |
Why?
|
Cell Lineage | 1 | 2021 | 2504 | 0.030 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2014 | 437 | 0.030 |
Why?
|
Plasma Exchange | 1 | 2013 | 152 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 2047 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2018 | 12356 | 0.030 |
Why?
|
Age Distribution | 1 | 2018 | 2902 | 0.030 |
Why?
|
Drug Evaluation | 1 | 2013 | 647 | 0.030 |
Why?
|
Age Factors | 1 | 2008 | 18373 | 0.020 |
Why?
|
Antigen-Presenting Cells | 1 | 2015 | 973 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2021 | 2043 | 0.020 |
Why?
|
Demography | 1 | 2016 | 1655 | 0.020 |
Why?
|
Crystallization | 1 | 2012 | 525 | 0.020 |
Why?
|
Nausea | 1 | 2014 | 674 | 0.020 |
Why?
|
Collagen Type I | 1 | 2014 | 592 | 0.020 |
Why?
|
Cell Compartmentation | 1 | 2012 | 402 | 0.020 |
Why?
|
HLA-DR Antigens | 1 | 2013 | 645 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2019 | 1170 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2182 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2018 | 1372 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2015 | 11366 | 0.020 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2015 | 571 | 0.020 |
Why?
|
Thromboembolism | 1 | 2017 | 987 | 0.020 |
Why?
|
Caregivers | 1 | 2022 | 2095 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 2011 | 356 | 0.020 |
Why?
|
Solubility | 1 | 2012 | 1088 | 0.020 |
Why?
|
Cell Fractionation | 1 | 2011 | 252 | 0.020 |
Why?
|
Aspirin | 1 | 2022 | 3283 | 0.020 |
Why?
|
Benzoquinones | 1 | 2011 | 201 | 0.020 |
Why?
|
Bone Resorption | 1 | 2014 | 723 | 0.020 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 652 | 0.020 |
Why?
|
Syndecan-1 | 1 | 2011 | 165 | 0.020 |
Why?
|
Transfection | 2 | 2015 | 5895 | 0.020 |
Why?
|
K562 Cells | 1 | 2012 | 635 | 0.020 |
Why?
|
Area Under Curve | 1 | 2014 | 1655 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2010 | 159 | 0.020 |
Why?
|
Immunoglobulins | 1 | 2013 | 881 | 0.020 |
Why?
|
Safety | 1 | 2014 | 1186 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2949 | 0.020 |
Why?
|
Chromosome Deletion | 1 | 2014 | 1401 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2018 | 2419 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2133 | 0.020 |
Why?
|
Job Application | 1 | 2009 | 39 | 0.020 |
Why?
|
Lactams, Macrocyclic | 1 | 2011 | 320 | 0.020 |
Why?
|
Young Adult | 3 | 2020 | 56429 | 0.020 |
Why?
|
Hemoglobins | 1 | 2015 | 1532 | 0.020 |
Why?
|
Financial Support | 1 | 2009 | 115 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4216 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3582 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2012 | 1879 | 0.020 |
Why?
|
Prevalence | 2 | 2017 | 15221 | 0.020 |
Why?
|
United States | 3 | 2020 | 69872 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2012 | 1802 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4554 | 0.020 |
Why?
|
Positron-Emission Tomography | 2 | 2015 | 6234 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 560 | 0.020 |
Why?
|
Central Nervous System | 1 | 2015 | 1357 | 0.020 |
Why?
|
Antigens, CD | 1 | 2018 | 4026 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2012 | 2556 | 0.020 |
Why?
|
Financing, Organized | 1 | 2009 | 202 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2011 | 692 | 0.020 |
Why?
|
Mice, SCID | 1 | 2012 | 2716 | 0.020 |
Why?
|
Temperature | 1 | 2013 | 2204 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3873 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2013 | 1607 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1915 | 0.020 |
Why?
|
Incidence | 2 | 2015 | 20952 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2274 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2018 | 1796 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2022 | 4245 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 4805 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2015 | 3207 | 0.020 |
Why?
|
Career Mobility | 1 | 2009 | 262 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2012 | 2242 | 0.020 |
Why?
|
Qualitative Research | 1 | 2015 | 2682 | 0.020 |
Why?
|
Risk Management | 1 | 2010 | 571 | 0.020 |
Why?
|
Drug Interactions | 1 | 2011 | 1460 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2012 | 2027 | 0.020 |
Why?
|
Cohort Studies | 2 | 2018 | 40559 | 0.020 |
Why?
|
Anticoagulants | 1 | 2021 | 4600 | 0.020 |
Why?
|
Proteins | 1 | 2021 | 6100 | 0.020 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2009 | 469 | 0.020 |
Why?
|
Drug Combinations | 1 | 2011 | 1958 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2020 | 9647 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2013 | 2216 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2076 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 1996 | 5867 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2011 | 1813 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 840 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2014 | 3203 | 0.010 |
Why?
|
Comorbidity | 1 | 2018 | 10388 | 0.010 |
Why?
|
Electrocardiography | 1 | 2017 | 6442 | 0.010 |
Why?
|
Mentors | 1 | 2009 | 631 | 0.010 |
Why?
|
Pneumonia | 1 | 2015 | 2133 | 0.010 |
Why?
|
Goals | 1 | 2009 | 707 | 0.010 |
Why?
|
Thrombosis | 1 | 2017 | 2968 | 0.010 |
Why?
|
Universities | 1 | 2009 | 951 | 0.010 |
Why?
|
Down-Regulation | 1 | 2011 | 3001 | 0.010 |
Why?
|
Cell Division | 1 | 2011 | 4569 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3154 | 0.010 |
Why?
|
Models, Molecular | 1 | 2013 | 5451 | 0.010 |
Why?
|
Risk Reduction Behavior | 1 | 2010 | 1125 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 2011 | 2513 | 0.010 |
Why?
|
Depression | 1 | 2022 | 7759 | 0.010 |
Why?
|
Neoplasms | 1 | 2012 | 21696 | 0.010 |
Why?
|
Risk | 1 | 2015 | 9688 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2009 | 956 | 0.010 |
Why?
|
Physician's Role | 1 | 2010 | 943 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2011 | 1524 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 5984 | 0.010 |
Why?
|
Cell Cycle | 1 | 2011 | 2967 | 0.010 |
Why?
|
Palliative Care | 1 | 2017 | 3493 | 0.010 |
Why?
|
Peptides | 1 | 2014 | 4410 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12262 | 0.010 |
Why?
|
Publishing | 1 | 2009 | 833 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2015 | 2736 | 0.010 |
Why?
|
Vaccination | 1 | 2013 | 3279 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2010 | 2108 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2018 | 21748 | 0.010 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 1378 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2015 | 13035 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 2012 | 2530 | 0.010 |
Why?
|
Pain | 1 | 2015 | 4988 | 0.010 |
Why?
|
Mitochondria | 1 | 2012 | 3514 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2219 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 2009 | 2760 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2013 | 4251 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9445 | 0.010 |
Why?
|
Models, Biological | 1 | 2014 | 9584 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3508 | 0.010 |
Why?
|
TATA Box | 1 | 1996 | 128 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1996 | 1085 | 0.010 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1996 | 708 | 0.010 |
Why?
|
Transcription Factor AP-1 | 1 | 1996 | 317 | 0.010 |
Why?
|
3T3 Cells | 1 | 1996 | 1101 | 0.010 |
Why?
|
Luciferases | 1 | 1996 | 733 | 0.010 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 1996 | 794 | 0.010 |
Why?
|
Adolescent | 1 | 2020 | 85779 | 0.010 |
Why?
|
Organ Specificity | 1 | 1996 | 2008 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 35425 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20130 | 0.010 |
Why?
|
Binding Sites | 1 | 1996 | 6111 | 0.000 |
Why?
|
Recombinant Proteins | 1 | 1996 | 6621 | 0.000 |
Why?
|
Fibroblasts | 1 | 1996 | 4162 | 0.000 |
Why?
|
Base Sequence | 1 | 1996 | 12797 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1996 | 18111 | 0.000 |
Why?
|
Cell Line | 1 | 1996 | 16000 | 0.000 |
Why?
|
Nuclear Proteins | 1 | 1996 | 5856 | 0.000 |
Why?
|
Transcription Factors | 1 | 1996 | 12207 | 0.000 |
Why?
|